Identification of New Markers in the Hypereosinophilic Syndrome

Related Clinical Trial
MAP to Provide Access to Nilotinib, for Patients With HES Eosinophilia Diagnosis A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Steroid Treatment for Hypereosinophilic Syndrome Natural History of Hypereosinophilia and Hypereosinophilic Syndromes A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Identification of New Markers in the Hypereosinophilic Syndrome A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

Brief Title

Identification of New Markers in the Hypereosinophilic Syndrome

Official Title

Identification of New Markers in the Hypereosinophilic Syndrome

Brief Summary

      The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and
      more accessible compared to those that we have already thanks to a proteomic approach. This
      will help the investigators to diagnose the this disease.
    



Study Type

Interventional


Primary Outcome

The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.


Condition

Hypereosinophilic Syndrome

Intervention

biologie sample

Study Arms / Comparison Groups

 Hypereosinophilic syndrome unexplained
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

41

Start Date

June 29, 2010

Completion Date

July 2015

Primary Completion Date

July 2015

Eligibility Criteria

        Inclusion Criteria:

          -  dated and signed informed consent

          -  virale serology negative or negative result less than 6 months

          -  virale serology negative for HBV or vaccinated patient

          -  insured

          -  virale serology negative or negative result less than 6 months

          -  negative pregnancy test or female menopause for at least 1 year

        Exclusion Criteria:

          -  subject enable adult, under guardianship or under protective measures of justice

          -  Refusal or inability to give informed consent

          -  The hypereosinophilic syndrome explained origin other than than atopy, bullous
             pemphigoid, the Churg-Strauss syndrome and DRESS
      

Gender

All

Ages

18 Years - 80 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Lionel Prin, MD PhD, , 

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT01713504

Organization ID

2008_29

Secondary IDs

2009-A00314-53

Responsible Party

Sponsor

Study Sponsor

University Hospital, Lille


Study Sponsor

Lionel Prin, MD PhD, Principal Investigator, University Hospital, Lille


Verification Date

February 2019